The purpose of this study is to characterize the PK of xanomeline and trospium in breast milk and plasma in healthy lactating female participants, following multiple oral administration of KarXT in healthy lactating participants.
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Maximum observed concentration (Cmax) of KarXT in Milk
Timeframe: Up to Day 7
Time of maximum observed concentration (Tmax) of KarXT in Milk
Timeframe: Up to Day 7
Area under the concentration-time curve from time zero to 12 hours post morning dose [AUC(0-12)] of KarXT in Milk
Timeframe: Up to Day 7
Area under the concentration-time curve from time zero to 24 hours post morning dose [AUC(0-24)] of KarXT in Milk
Timeframe: Up to Day 7
Average concentration (Cavg) of KarXT in Milk
Timeframe: Up to Day 7
Amount of KarXT recovered in milk within 12 hours of dosing [AR(12)]
Timeframe: Up to Day 7
Total amount of KarXT recovered in milk (AR)
Timeframe: Up to Day 7
Milk-plasma ratio of KarXT (M/P)
Timeframe: Up to Day 7